American Diabetes Association

An analysis of the DECLARE-TIMI 58 trial suggests dapagliflozin use could reduce the risk of fast decline in eGFR.

Examining the results of MEX0114, a phase 2 trial evaluating the use of ladarixin in patients with new-onset type 1 diabetes.

An investigator provides an update on the TEDDY study.

Sirimon Reutrakul, MD, discusses what providers should do based on the findings of a new study presented at ADA 2020.

A leader in the field diabetic care, and endocrinology as a whole, Bruce Bode, MD, offers invaluable perspective on the impact of COVID-19 on clinical practice and major trials.

The monitor is approved for children and adults 4 years and older with diabetes.

Results of a new study are diving deeper into potential mediators of the effects of canagliflozin on heart failure and CV death seen in CREDENCE.

A prespecified exploratory analysis suggests the SGLT2 inhibitor reduced the rate of new-onset diabetes by nearly a third.

Chief Medical Officer of Applied Therapeutics discusses a study presented at ADA 2020 examining use of an aldose reductase inhibitor for diabetic complications.

Patients living in states that chose to expand Medicaid coverage might be seeking care earlier to prevent major leg amputation.

Results of the EXPERT study could help guide clinical decision making for GLP-1 RA-experienced patients.

Christopher Sorli, MD, describes the results of a study showing the need for simultaneous therapy rather than sequential.

Discussing a look at the current life expectancy of patients with T2DM with an assistant professor from the University of Florida’s College of Pharmacy.

Discussing the results of a phase 2 study from Diasome examining use of HDV-insulin in type 1 diabetics.

Silvio Inzucchi, MD, discusses an EMPA-REG OUTCOME analysis assessing the impact of empagliflozin in patients who experience an initial dip in eGFR.

Bruce Bode, MD, discusses the results of a proof-of-concept study examining insulin and glucagon coadministration to prevent hypoglycemia and hyperglycemia in type 1 diabetics.

Deepak Bhatt, MD, MPH, discusses the results of the latest REDUCE-IT analysis, titled REDUCE-IT DIABETES, presented at ADA 2020.

Kieran Docherty, MBChB, discusses the results of a DAPA-HF analysis he presented at ADA 2020.

Hospitalization rates decrease 52% for patients with type 1 diabetes and 47% for patients with type 2 diabetes.

The intervention model can be used to help manage a variety of chronic diseases.

Discussing the effect of canagliflozin in patients with diabetes and chronic kidney disease with Meg Jardine, MBBS, PhD.

Survey findings highlight the psychological and psychosocial distress related to having diabetes.

More patients achieve international time in range consensus target of greater than 70% with the Advanced system.

A recent analysis is examining potential factors associated with adverse gastrointestinal events in patients using semaglutide and whether it mitigates benefit.

Discussing data from ADA 2020 with a professor of medicine at University of Texas Southwestern.

After Janssen's submission of an sNDA in March, results of the CREDENCE subgroup analyses were among the most anticipated presentations at ADA 2019.

A study presented at ADA 2019 examined the efficacy of sitagliptin compared with dapagliflozin in t2d patients 65 years old and older.

A 6-month study examining the effects of hepatic-directed prandial insulin in patients with type 1 diabetes mellitus was presented at ADA 2019.

Osama Hamdy, MD, PhD, discusses the impact of a 10-year study observing the impact of lifestyle interventions among diabetes patients in real-world clinical practice.

Investigators presented results of a study that analyzed renal function and markers of kidney damage in more than 1,000 patients in two randomized trials examining ertugliflozin.